Relapse/Recurrence Prevention in Major Depressive Disorder: 26-Month Follow-Up of Mindfulness-Based Cognitive Therapy...

Area of Science:

• Psychiatry
• Clinical Psychology
• Neuroscience

Background:

• Major depressive disorder relapse is a significant clinical challenge.
• Mindfulness-Based Cognitive Therapy (MBCT) is a recognized intervention for preventing depressive relapse.
• Previous studies suggest MBCT's efficacy, necessitating long-term comparative analyses.

Purpose of the Study:

• To compare the long-term effectiveness of MBCT versus a rigorous active control condition (ACC) for preventing depressive relapse/recurrence.
• To assess the impact of MBCT and ACC on depressive symptoms and life satisfaction over a 26-month follow-up period.
• To investigate the durability of treatment effects beyond the initial 12-month post-intervention period.

Main Methods:

• A 26-month follow-up of a randomized controlled trial comparing an 8-week MBCT group (n=46) to an ACC (n=46) in participants with major depression remission.
• Intention-to-treat analyses were employed to assess outcomes at baseline, post-intervention, and at 6, 12, and 26 months.
• Time to relapse was analyzed using hazard ratios, and piecewise analyses examined changes in depressive symptoms over time.

Main Results:

• No significant differences were found between MBCT and ACC in preventing depression relapse, reducing depressive symptoms, or improving life satisfaction over 26 months.
• Relapse rates were similar: 47.8% for MBCT and 50.0% for ACC (hazard ratio = 0.82, 95% CI [.34, 1.99]).
• Initial symptom declines observed with MBCT post-intervention were not sustained after 12 months; both groups showed a slight rebound but remained improved from baseline at 26 months.

Conclusions:

• MBCT demonstrated no superior efficacy compared to a rigorous ACC in the long-term prevention of major depression relapse or enhancement of well-being.
• The findings suggest that both MBCT and ACC may confer similar therapeutic benefits, potentially due to factors beyond specific therapeutic mechanisms.
• Future research should include treatment-as-usual (TAU) control groups to differentiate specific treatment effects from non-specific or time-related factors and to validate the comparative efficacy of MBCT.